APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon Like Peptide-1 (GLP-1) Agonists

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Selected research

Industry Research

Glucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026

25 December 2025119 pages

Choose your research edition.

Industry ResearchGlucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Read the full market overview

Report Scope

This report quantifies the global Glucagon Like Peptide-1 (GLP-1) Agonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Glucagon Like Peptide-1 (GLP-1) Agonists Market by Company

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

Hospital

Pharmacy

Other

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Glucagon Like Peptide-1 (GLP-1) Agonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue of Manufacturers (2021-2026) Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Manufacturers (2021-2026) Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novo Nordisk Company Information Table 19. Novo Nordisk Business Overview Table 20. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 21. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 22. Novo Nordisk Recent Developments Table 23. AstraZeneca Company Information Table 24. AstraZeneca Business Overview Table 25. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 26. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 27. AstraZeneca Recent Developments Table 28. Eli Lily Company Information Table 29. Eli Lily Business Overview Table 30. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 31. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 32. Eli Lily Recent Developments Table 33. GSK Company Information Table 34. GSK Business Overview Table 35. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 36. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 37. GSK Recent Developments Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 41. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 42. Sanofi Recent Developments Table 43. Bristol-Myers Squibb Company Information Table 44. Bristol-Myers Squibb Business Overview Table 45. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 46. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 47. Bristol-Myers Squibb Recent Developments Table 48. Amylin Company Information Table 49. Amylin Business Overview Table 50. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 51. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 52. Amylin Recent Developments Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (K Units) Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2026) Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2027-2032) & (K Units) Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2027-2032) Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2026) Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2027-2032) Table 62. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 64. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 65. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2026) & (US$ Million) Table 66. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2027-2032) & (US$ Million) Table 67. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 69. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 70. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2026) & (US$ Million) Table 71. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2027-2032) & (US$ Million) Table 72. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 74. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 75. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2026) & (US$ Million) Table 76. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2027-2032) & (US$ Million) Table 77. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 79. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 80. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2026) & (US$ Million) Table 81. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2027-2032) & (US$ Million) Table 82. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 84. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 85. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2026) & (US$ Million) Table 86. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2027-2032) & (US$ Million) Table 87. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 88. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 89. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2026) Table 90. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2027-2032) Table 91. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (US$ Million) Table 92. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (US$ Million) Table 93. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2026) Table 94. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2027-2032) Table 95. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2026) & (USD/Unit) Table 96. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2027-2032) & (USD/Unit) Table 97. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 98. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 99. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2026) Table 100. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2027-2032) Table 101. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (US$ Million) Table 102. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (US$ Million) Table 103. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2026) Table 104. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2027-2032) Table 105. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2026) & (USD/Unit) Table 106. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2027-2032) & (USD/Unit) Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List Table 110. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List Table 111. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends Table 112. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers Table 113. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints Table 114. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Glucagon Like Peptide-1 (GLP-1) Agonists Product Image Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (2021-2032) & (US$ Million) Figure 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032) & (K Units) Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) & (2021-2032) Figure 9. Exenatied Product Image Figure 10. Liraglutide Product Image Figure 11. Lixisenatide Product Image Figure 12. Albiglutide Product Image Figure 13. Dulaglutide Product Image Figure 14. Hospital Product Image Figure 15. Pharmacy Product Image Figure 16. Other Product Image Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region in 2025 Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region in 2025 Figure 24. North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country in 2025 Figure 25. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 26. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021-2032) Figure 27. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country in 2025 Figure 31. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 32. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021-2032) Figure 33. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country in 2025 Figure 44. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021-2032) Figure 46. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country in 2025 Figure 55. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 56. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021-2032) Figure 57. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Colombia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country in 2025 Figure 62. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2021-2032) Figure 64. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032) Figure 70. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032) Figure 71. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2021-2032) Figure 72. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032) Figure 73. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032) Figure 74. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2021-2032) Figure 75. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Figure 76. Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Exenatied
  • Liraglutide
  • Lixisenatide
  • Albiglutide
  • Dulaglutide
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb
  • Amylin

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (2021-2032)
  4. 2.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032)
  5. 2.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2021-2032)
  6. 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Exenatied
  9. 2.3.3 Liraglutide
  10. 2.3.4 Lixisenatide
  11. 2.3.5 Albiglutide
  12. 2.3.6 Dulaglutide
  13. 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Pharmacy
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application
  8. 3.8 Global Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Established Date
  9. 3.9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novo Nordisk
  2. 4.1.1 Novo Nordisk Company Information
  3. 4.1.2 Novo Nordisk Business Overview
  4. 4.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  6. 4.1.5 Novo Nordisk Recent Developments
  7. 4.2 AstraZeneca
  8. 4.2.1 AstraZeneca Company Information
  9. 4.2.2 AstraZeneca Business Overview
  10. 4.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  12. 4.2.5 AstraZeneca Recent Developments
  13. 4.3 Eli Lily
  14. 4.3.1 Eli Lily Company Information
  15. 4.3.2 Eli Lily Business Overview
  16. 4.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  18. 4.3.5 Eli Lily Recent Developments
  19. 4.4 GSK
  20. 4.4.1 GSK Company Information
  21. 4.4.2 GSK Business Overview
  22. 4.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  24. 4.4.5 GSK Recent Developments
  25. 4.5 Sanofi
  26. 4.5.1 Sanofi Company Information
  27. 4.5.2 Sanofi Business Overview
  28. 4.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  30. 4.5.5 Sanofi Recent Developments
  31. 4.6 Bristol-Myers Squibb
  32. 4.6.1 Bristol-Myers Squibb Company Information
  33. 4.6.2 Bristol-Myers Squibb Business Overview
  34. 4.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  36. 4.6.5 Bristol-Myers Squibb Recent Developments
  37. 4.7 Amylin
  38. 4.7.1 Amylin Company Information
  39. 4.7.2 Amylin Business Overview
  40. 4.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  42. 4.7.5 Amylin Recent Developments
5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Scenario by Region
  1. 5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021-2032
  3. 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021-2026
  4. 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2027-2032
  5. 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021-2032
  6. 5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021-2026
  7. 5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2027-2032
  8. 5.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
  9. 5.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  11. 5.4.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
  16. 5.5.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  18. 5.5.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
  41. 5.7.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  43. 5.7.3 South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  2. 6.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  5. 6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  2. 7.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  5. 7.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
  2. 8.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
  5. 8.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
  8. 8.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Analyzing Market Dynamics
  1. 9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
  2. 9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
  3. 9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
  4. 9.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst